Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Pharma & Biotech